Building a market access blueprint for lung cancer diagnostics in Asia-Pacific Lung cancer is the leading cause of cancer mortality in the… Cancer diagnostics | Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Asia | Global | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx)
How Indonesia’s healthcare transformation will impact its IVD market Indonesia’s in-vitro diagnostics (IVD) market will recover… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Asia | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
How Vision 2030 is driving growth in Saudi Arabia’s IVD market The incidence of cardiovascular diseases (CVD) in… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx)
Middle East IVD market to recover to pre-pandemic growth rates from 2024 The Middle East IVD market has mostly recovered to… Centralised Diagnostics (CEDx) | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Cancer biomarker testing to grow in Asia The cancer burden in Asia is increasing, with new cancer… Cancer diagnostics | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Size and Share Plus | The Gateway
Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge The impact of China’s latest covid-19 surge heads the… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx)
Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels Asia-Pacific (APAC) IVD markets have grown and exceeded… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | Infectious Diseases Testing Monitor | IVD Gateway | Molecular Diagnostics (MDx)
Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5 Larger gene panels are the predominant NGS testing strategy… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Insights into Europe’s covid-19 testing and technology use 2021-2022: PCR v serology v antigen Europe is shifting its covid-19-approach from pandemic to… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Molecular Diagnostics (MDx) | Europe | IVD Gateway | Molecular Diagnostics (MDx)